These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 444376)

  • 1. Spironolactone response related to plasma canrenone concentration [proceedings].
    Hettiarachchi J; Ramsay LE
    Br J Clin Pharmacol; 1979 Apr; 7(4):426P-427P. PubMed ID: 444376
    [No Abstract]   [Full Text] [Related]  

  • 2. High-performance liquid chromatographic determination of canrenone, a major metabolite of spironolactone, in body fluids.
    Neurath GB; Ambrosius D
    J Chromatogr; 1979 Jun; 163(2):230-5. PubMed ID: 541378
    [No Abstract]   [Full Text] [Related]  

  • 3. Enhancement by food of canrenone bioavailability from spironolactone.
    Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
    Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours.
    Merkus FW; Overdiek JW; Cilissen J; Zuidema J
    Clin Exp Hypertens A; 1983; 5(2):239-48. PubMed ID: 6831747
    [No Abstract]   [Full Text] [Related]  

  • 5. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
    Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
    Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.
    Karim A; Zagarella J; Hutsell TC; Dooley M
    Clin Pharmacol Ther; 1976 Feb; 19(2):177-82. PubMed ID: 1261155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is canrenone the major metabolite of spironolactone?
    Merkus FW
    Clin Pharm; 1983; 2(3):209-10. PubMed ID: 6883952
    [No Abstract]   [Full Text] [Related]  

  • 8. Influence of spironolactone and its metabolite canrenone on serum digoxin assays.
    Foukaridis GN
    Ther Drug Monit; 1990 Jan; 12(1):82-4. PubMed ID: 2305425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of spironolactone and its metabolite, canrenone, in human serum by thin-layer spectrofluorimetry.
    van der Merwe PJ; Müller DG; Clark EC
    J Chromatogr; 1979 Apr; 171():519-21. PubMed ID: 546864
    [No Abstract]   [Full Text] [Related]  

  • 10. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
    Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
    Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proceedings: Acute and chronic effects of the aldosterone antagonist spironolactone and its main metabolite canrenone on plasma aldosterone concentration, plasma renin activity, serum electrolytes and on the excretion of aldosterone, fluid and electrolytes in rats.
    Erbler HC; Hilfenhaus M
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R52. PubMed ID: 1143449
    [No Abstract]   [Full Text] [Related]  

  • 12. Application of a simple fluorometric method on absorption of canrenone.
    Radó JP; Szende L; Takó J; Nagy O; Kozma C
    Int J Clin Pharmacol Biopharm; 1976 Mar; 13(2):123-6. PubMed ID: 1254376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
    Krause W; Karras J; Jakobs U
    J Chromatogr; 1983 Oct; 277():191-9. PubMed ID: 6643605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples.
    Sandall JM; Millership JS; Collier PS; McElnay JC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jul; 839(1-2):36-44. PubMed ID: 16510319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.
    Dahlöf CG; Lundborg P; Persson BA; Regårdh CG
    Drug Metab Dispos; 1979; 7(2):103-7. PubMed ID: 38071
    [No Abstract]   [Full Text] [Related]  

  • 16. Elimination of canrenone in congestive heart failure and chronic liver disease.
    Jackson L; Branch R; Levine D; Ramsay L
    Eur J Clin Pharmacol; 1977 Mar; 11(3):177-9. PubMed ID: 852495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone.
    Ho PC; Bourne DW; Triggs EJ; Smithurst BA
    Eur J Clin Pharmacol; 1984; 27(4):435-9. PubMed ID: 6519150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of neomycin on the bioavailability of spironolactone: a single-dose study.
    Bartle WR; Coates PE; Fisher MM; Louman FJ
    Am J Hosp Pharm; 1979 Dec; 36(12):1701-3. PubMed ID: 525647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone.
    Platt D; Abshagen U; Mühlberg W; Horn HJ; Schmitt-Rüth R; Vollmar J
    Arch Gerontol Geriatr; 1984 Jul; 3(2):147-59. PubMed ID: 6476975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of spironolactone and its main metabolite canrenone on the renin-angiotensin-aldosterone-system during long-term treatment in rats.
    Erbler HC
    Acta Endocrinol (Copenh); 1979 Jan; 90(1):147-56. PubMed ID: 760354
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.